BIOFILCHEMPharmaceuticals
Biofil Chemicals & Pharmaceuticals Ltd — Cash Flow Statement
₹25.79
-4.48%
Biofil Chemicals & Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -2.02 Cr | 2.37 Cr | -0.12 Cr | -0.29 Cr | — |
| Capital Expenditure | -0.10 Cr | -0.02 Cr | -0.01 Cr | -0.07 Cr | — |
| End Cash Position | 0.26 Cr | 2.28 Cr | 0.04 Cr | 0.14 Cr | — |
| Beginning Cash Position | 2.28 Cr | 0.04 Cr | 0.14 Cr | 0.44 Cr | — |
| Changes In Cash | -2.03 Cr | 2.25 Cr | -0.11 Cr | -0.30 Cr | — |
| Financing Cash Flow | -45000.00 | -0.12 Cr | 0.02 Cr | -58000.00 | — |
| Interest Paid Cff | -0.04 Cr | -0.04 Cr | -0.04 Cr | -0.04 Cr | — |
| Net Issuance Payments Of Debt | 0.03 Cr | -0.08 Cr | 0.06 Cr | 0.03 Cr | — |
| Net Long Term Debt Issuance | 0.03 Cr | -0.08 Cr | 0.06 Cr | 0.03 Cr | — |
| Investing Cash Flow | -0.10 Cr | -0.02 Cr | -0.01 Cr | -0.07 Cr | — |
| Interest Received Cfi | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net PPE Purchase And Sale | -0.10 Cr | -0.02 Cr | -0.01 Cr | -0.07 Cr | — |
| Sale Of PPE | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Purchase Of PPE | -0.10 Cr | -0.02 Cr | -0.01 Cr | -0.07 Cr | — |
| Operating Cash Flow | -1.92 Cr | 2.39 Cr | -0.11 Cr | -0.22 Cr | — |
| Taxes Refund Paid | -0.18 Cr | -0.16 Cr | -0.23 Cr | -0.32 Cr | — |
| Change In Working Capital | -2.92 Cr | 1.05 Cr | -1.05 Cr | -1.40 Cr | — |
| Change In Other Current Liabilities | -0.17 Cr | -0.05 Cr | 0.10 Cr | 61000.00 | — |
| Change In Other Current Assets | -0.11 Cr | 0.06 Cr | 0.05 Cr | 0.76 Cr | — |
| Change In Payable | 3.43 Cr | 14.90 Cr | 12.05 Cr | -15.26 Cr | — |
| Change In Inventory | -0.79 Cr | -1.34 Cr | 0.08 Cr | 3.05 Cr | — |
| Change In Receivables | -5.29 Cr | -12.53 Cr | -13.33 Cr | 10.04 Cr | — |
| Other Non Cash Items | 0.04 Cr | 0.04 Cr | 0.04 Cr | 0.04 Cr | — |
| Depreciation And Amortization | 0.38 Cr | 0.40 Cr | 0.43 Cr | 0.44 Cr | — |
| Depreciation | 0.38 Cr | 0.40 Cr | 0.43 Cr | 0.44 Cr | — |
| Pension And Employee Benefit Expense | 0.02 Cr | 0.19 Cr | -0.10 Cr | 0.01 Cr | — |
| Net Income From Continuing Operations | 0.74 Cr | 0.87 Cr | 0.79 Cr | 1.01 Cr | — |
| Net Other Financing Charges | — | 8.26 Cr | — | — | — |
| Provisionand Write Offof Assets | — | 0.00 | 0.00 | — | — |
| Net Short Term Debt Issuance | — | — | 0.06 Cr | 0.03 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | — | — | -1000.00 | — |
| Dividends Received Cfi | — | — | — | — | 0.00 |
| Net Investment Purchase And Sale | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Biofil Chemicals & Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.